Efficacy of SGLT2 Inhibitors in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Preclinical Studies

This systematic review and meta-analysis of nine preclinical studies demonstrates that SGLT2 inhibitors significantly improve pulmonary hemodynamics and right ventricular function in animal models of pulmonary arterial hypertension, suggesting their potential as a novel therapeutic strategy.

The Gist

The Big Picture: A Clogged Highway and a New Kind of Traffic Cop

Imagine your lungs and heart as a busy city. The pulmonary arteries are the main highways carrying blood from the heart to the lungs to pick up oxygen.

In a disease called Pulmonary Arterial Hypertension (PAH), these highways get clogged. The walls of the roads thicken, the lanes get narrower, and traffic jams (high pressure) build up. This forces the heart's right side (the pump that sends blood to the lungs) to work overtime. Eventually, the pump gets too tired, swells up (hypertrophy), and starts to fail.

Currently, doctors have "traffic cops" (medicines) that try to widen the lanes to let cars flow better. But sometimes, the roads are so damaged that just widening them isn't enough. We need a way to actually repair the road walls and stop the construction crews from making them thicker.

The New Candidate: The "Sugar-Siphon" Drugs

Enter SGLT2 inhibitors. You might know these as drugs originally designed for diabetes. Think of them as "sugar siphons." They work by telling the kidneys to dump extra sugar into the urine instead of keeping it in the blood.

But scientists noticed something interesting: these "sugar siphons" also seem to act like mechanic's tools for the heart and blood vessels. They reduce inflammation, stop the "construction crews" (cells) from overbuilding, and help the heart pump more efficiently.

The Study: Testing the Mechanics in the Lab

Since we can't test new drugs on humans with PAH immediately (it's too risky), scientists first test them on animals. This paper is a Systematic Review and Meta-Analysis.

• The Systematic Review: Imagine nine different mechanics (scientists) working in nine different garages (labs). They all tested if the "sugar siphon" drugs could fix the clogged highways in rats and mice.
• The Meta-Analysis: Instead of looking at each mechanic's report separately, the authors of this paper gathered all nine reports, put them in a giant blender, and calculated the average result. This gives a much clearer picture of whether the drug actually works.

What They Found: The Results

The researchers looked at five key things to see if the "sugar siphon" helped:

1. Pressure in the Lungs (mPAP & RVSP):

   • The Analogy: Is the water pressure in the pipes lower?
   • The Result: Yes! The drugs significantly lowered the pressure. It's like the traffic jams cleared up, and the cars started moving freely again.

2. Heart Size (RV/LV+S):

   • The Analogy: Did the heart pump stop getting swollen and tired?
   • The Result: Yes. The right side of the heart stopped getting as big and bulky. It was like the pump stopped straining and returned to a normal, healthy size.

3. Heart Movement (TAPSE & PAAT):

   • The Analogy: Is the pump squeezing strongly and efficiently?
   • The Result: Yes. The heart's movement became stronger and faster. It was like the pump went from a sluggish, heavy lift to a snappy, efficient squeeze.

The "Why" and the "But"

Why did it work?
The paper suggests these drugs don't just lower sugar; they act like anti-inflammatory fire extinguishers. They stop the chemical fires (oxidative stress and inflammation) that cause the blood vessel walls to thicken. They also tell the cells to stop building extra road walls and start cleaning up the mess.

The Catch (Limitations):

• Animal vs. Human: These tests were done on rats and mice. Animals are not humans. Just because a car engine works in a toy model doesn't mean it works in a real Ferrari.
• Small Sample: Only nine studies were included. It's like having nine chefs try a new recipe; it's a good start, but we need more chefs to be sure the dish is perfect.
• One Outlier: One study found the drug didn't work. This is like one mechanic saying, "My car didn't get fixed." It suggests that maybe the timing or the specific type of animal matters.

The Bottom Line

This paper is a very promising sign. It suggests that drugs currently used for diabetes (SGLT2 inhibitors) might be a "secret weapon" for treating Pulmonary Arterial Hypertension. They seem to lower pressure, shrink the swollen heart, and help the heart pump better in animal models.

What's next?
We need to move from the "toy garage" (animal labs) to the "real world" (human clinical trials). If these drugs work in humans the way they did in the rats, we might have a new, powerful tool to help people with PAH breathe easier and live longer.

In short: The "sugar siphon" drugs might just be the double-duty mechanic the heart needs to fix the clogged highways of the lungs.

Technical Summary

1. Problem Statement

Pulmonary Arterial Hypertension (PAH) is a progressive, fatal disease characterized by vascular remodeling, elevated pulmonary vascular resistance, and right ventricular (RV) failure. Current standard therapies (vasodilators targeting NO, prostacyclin, and endothelin pathways) improve symptoms but have limited impact on long-term mortality.
The Gap: While Sodium-Glucose Cotransporter-2 inhibitors (SGLT2i) have demonstrated significant cardioprotective benefits in left heart failure and diabetes, their efficacy in PAH remains unclear. Preclinical literature presents conflicting results: some studies suggest SGLT2i mitigate RV remodeling and improve hemodynamics, while others (e.g., Li et al., 2021) report no protective effect. There is a lack of quantitative synthesis to resolve these contradictions and guide translational research.

2. Methodology

The study adhered to SYRCLE guidelines for preclinical systematic reviews and was registered in PROSPERO (CRD42024627817).

• Search Strategy: A comprehensive search was conducted on November 10, 2024, across PubMed, Embase, Web of Science, and Scopus.
• Inclusion Criteria:
  • Experimental animal studies (rats, mice, pigs) with Group 1 PAH.
  • Intervention with SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin, canagliflozin).
  • Presence of a control group.
  • Quantitative reporting of hemodynamic or structural outcomes.
• Exclusion Criteria: Non-primary research, non-English studies, in vitro/in silico models, and studies lacking specific cardiovascular metrics.
• Data Extraction & Quality: Two independent reviewers extracted data on study characteristics, induction methods (Monocrotaline, Sugen/hypoxia), dosing, and outcomes. Risk of bias was assessed using the SYRCLE Risk of Bias tool.
• Statistical Analysis:
  • Model: Random-effects meta-analysis (DerSimonian and Laird method) using R software (meta and metafor packages).
  • Effect Measure: Weighted Mean Difference (WMD) with 95% Confidence Intervals (CI).
  • Heterogeneity: Assessed via $I^2$ and $\tau^2$.
  • Subgroup/Sensitivity: Analyses were performed by drug type and animal model; leave-one-out analysis tested robustness. Publication bias was not assessed due to the small number of studies (<10 per outcome).

3. Key Contributions

• First Quantitative Synthesis: This is the first meta-analysis to quantitatively aggregate preclinical evidence regarding SGLT2i in PAH, addressing the inconsistency in individual study findings.
• Multi-Dimensional Assessment: The study evaluates a comprehensive range of outcomes, including:
  • Hemodynamics: Mean Pulmonary Artery Pressure (mPAP), Right Ventricular Systolic Pressure (RVSP).
  • Structural Remodeling: Right Ventricular Hypertrophy Index (RV/LV+S).
  • Functional Metrics: Tricuspid Annular Plane Systolic Excursion (TAPSE) and Pulmonary Artery Acceleration Time (PAAT).
• Mechanistic Insight: The review synthesizes proposed mechanisms of action, linking SGLT2i efficacy to reduced oxidative stress, inhibition of endothelial-to-mesenchymal transition (EndoMT), and attenuation of vascular smooth muscle proliferation.

4. Results

Nine preclinical studies (published 2020–2024), involving primarily rodent models (8 rat, 1 mixed rat/mouse), were included.

• Hemodynamic Improvements:
  • mPAP: SGLT2i significantly reduced mean pulmonary artery pressure (WMD: −9.79 mmHg; 95% CI: −14.67 to −4.92; $p < 0.0001$). Heterogeneity was negligible ($I^2 = 0\%$).
  • RVSP: Significant reduction in right ventricular systolic pressure (WMD: −14.81 mmHg; 95% CI: −19.50 to −10.12; $p < 0.0001$). Moderate heterogeneity was observed ($I^2 = 63.4\%$).
• Structural and Functional Benefits:
  • RV Hypertrophy: Significant reduction in the RV/LV+S ratio (WMD: −0.10; 95% CI: −0.12 to −0.07; $p < 0.0001$), indicating attenuated right ventricular hypertrophy.
  • RV Function: Significant improvement in TAPSE (WMD: 0.53 mm; $p = 0.0008$) and PAAT (WMD: 6.39 ms; $p < 0.0001$), suggesting enhanced systolic function and reduced pulmonary vascular resistance.
• Subgroup Analyses:
  • Drug Class: Efficacy was consistent across dapagliflozin, empagliflozin, and canagliflozin, with no statistically significant differences between specific agents for most outcomes, suggesting a class effect.
  • Animal Models: Results were consistent across different induction models (Monocrotaline vs. Sugen/hypoxia).
• Safety: No significant adverse effects were reported in the included studies. Some data suggested a survival benefit and weight loss consistent with known SGLT2i profiles.

5. Significance and Limitations

Significance:

• Therapeutic Potential: The findings strongly support the hypothesis that SGLT2 inhibitors offer cardioprotective and anti-remodeling benefits in PAH beyond their metabolic effects.
• Translational Bridge: By confirming efficacy across diverse preclinical models, the study provides a robust rationale for initiating human clinical trials to evaluate SGLT2i as an adjunct therapy for PAH.
• Mechanistic Validation: The results align with proposed mechanisms involving the reduction of oxidative stress, inflammation, and vascular smooth muscle proliferation.

Limitations:

• Sample Size: The meta-analysis included only 9 studies, with some outcomes (e.g., mPAP) based on only 3 studies, limiting statistical power.
• Heterogeneity: Moderate heterogeneity in RVSP and TAPSE outcomes suggests variability in experimental protocols (e.g., anesthesia, measurement techniques).
• Preclinical Nature: Animal models (often acute induction) may not fully replicate the chronic, complex pathophysiology of human PAH.
• Publication Bias: Formal assessment of publication bias was not possible due to the low number of studies, raising the possibility that negative results may be underreported.

Conclusion:
This meta-analysis provides compelling preclinical evidence that SGLT2 inhibitors significantly improve pulmonary hemodynamics and right ventricular function in animal models of PAH. These findings justify further investigation into the translational potential of SGLT2i for treating pulmonary arterial hypertension in humans.